{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:45:35Z","timestamp":1792683935082,"version":"4.5.0"},"reference-count":178,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bcp.2026.118559","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:20:17Z","timestamp":1792682417000},"page":"118559","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Isoliquiritigenin in breast cancer therapy: from mechanistic insights to advanced nano-enabled delivery strategies"],"prefix":"10.1016","author":[{"given":"Kumar","family":"Ganesan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gao","family":"Yuanze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxia","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6494-5271","authenticated-orcid":false,"given":"Jianping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bcp.2026.118559_b0005","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.bcp.2026.118559_b0010","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: a review","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.bcp.2026.118559_b0015","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.3390\/cancers15041320","article-title":"Targeted therapy and mechanisms of drug resistance in breast cancer","volume":"15","author":"Kinnel","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.bcp.2026.118559_b0020","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/nm.4409","article-title":"Cancer stem cells revisited","volume":"23","author":"Batlle","year":"2017","journal-title":"Nat. Med."},{"issue":"18","key":"10.1016\/j.bcp.2026.118559_b0025","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1007\/s00018-015-1920-4","article-title":"Cancer stem cells: a potential target for cancer therapy","volume":"72","author":"Qiu","year":"2015","journal-title":"Cell. Mol. Life Sci."},{"issue":"5","key":"10.1016\/j.bcp.2026.118559_b0030","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41568-021-00332-6","article-title":"Linking EMT programmes to normal and neoplastic epithelial stem cells","volume":"21","author":"Lambert","year":"2021","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.bcp.2026.118559_b0035","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.cell.2008.03.027","article-title":"The epithelial-mesenchymal transition generates cells with properties of stem cells","volume":"133","author":"Mani","year":"2008","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.bcp.2026.118559_b0040","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.tcb.2018.12.001","article-title":"EMT transition states during tumor progression and metastasis","volume":"29","author":"Pastushenko","year":"2019","journal-title":"Trends Cell Biol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118559_b0045","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3390\/ijms19010263","article-title":"Plant secondary metabolites as anticancer agents: successes in clinical trials and therapeutic application","volume":"19","author":"Seca","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"Suppl 2","key":"10.1016\/j.bcp.2026.118559_b0050","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000443404","article-title":"Natural products as a vital source for the discovery of cancer chemotherapeutic and chemopreventive agents","volume":"25","author":"Cragg","year":"2016","journal-title":"Med. Princ. Pract."},{"issue":"14","key":"10.1016\/j.bcp.2026.118559_b0055","doi-asserted-by":"crossref","DOI":"10.3390\/cells11142209","article-title":"The role of natural products and their multitargeted approach to treat solid cancer","volume":"11","author":"Muhammad","year":"2022","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.bcp.2026.118559_b0060","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2174\/1568009614666140122160515","article-title":"Molecular targeted approaches to cancer therapy and prevention using chalcones","volume":"14","author":"Jandial","year":"2014","journal-title":"Curr. Cancer Drug Targets"},{"issue":"12","key":"10.1016\/j.bcp.2026.118559_b0065","doi-asserted-by":"crossref","first-page":"7762","DOI":"10.1021\/acs.chemrev.7b00020","article-title":"Chalcone: a privileged structure in medicinal chemistry","volume":"117","author":"Zhuang","year":"2017","journal-title":"Chem. Rev."},{"issue":"7","key":"10.1016\/j.bcp.2026.118559_b0070","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1002\/ptr.5348","article-title":"The pharmacology of isoliquiritigenin","volume":"29","author":"Peng","year":"2015","journal-title":"Phytother. Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.118559_b0075","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/13880209.2016.1225775","article-title":"The anti-inflammatory activity of licorice, a widely used Chinese herb","volume":"55","author":"Yang","year":"2017","journal-title":"Pharm. Biol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118559_b0080","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.lfs.2004.09.047","article-title":"Isoliquiritigenin induces apoptosis and cell cycle arrest through p53-dependent pathway in Hep G2 cells","volume":"77","author":"Hsu","year":"2005","journal-title":"Life Sci."},{"issue":"2","key":"10.1016\/j.bcp.2026.118559_b0085","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.cbi.2006.03.008","article-title":"Liquiritigenin, an aglycone of liquiritin in Glycyrrhizae radix, prevents acute liver injuries in rats induced by acetaminophen with or without buthionine sulfoximine","volume":"161","author":"Kim","year":"2006","journal-title":"Chem. Biol. Interact."},{"issue":"6a","key":"10.1016\/j.bcp.2026.118559_b0090","first-page":"3949","article-title":"Chalcones: structural requirements for antioxidant, estrogenic and antiproliferative activities","volume":"21","author":"Calliste","year":"2001","journal-title":"Anticancer Res"},{"issue":"4\u20135","key":"10.1016\/j.bcp.2026.118559_b0095","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0960-0760(02)00230-3","article-title":"Estrogenic and antiproliferative activities of isoliquiritigenin in MCF7 breast cancer cells","volume":"82","author":"Maggiolini","year":"2002","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118559_b0100","doi-asserted-by":"crossref","first-page":"9022","DOI":"10.1038\/s41598-017-08422-y","article-title":"Isoliquiritigenin modulates miR-374a\/PTEN\/Akt axis to suppress breast cancer tumorigenesis and metastasis","volume":"7","author":"Peng","year":"2017","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.bcp.2026.118559_b0105","doi-asserted-by":"crossref","first-page":"9854","DOI":"10.18632\/oncotarget.3396","article-title":"Dietary compound isoliquiritigenin prevents mammary carcinogenesis by inhibiting breast cancer stem cells through WIF1 demethylation","volume":"6","author":"Wang","year":"2015","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.bcp.2026.118559_b0110","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1093\/carcin\/bgu187","article-title":"Dietary compound isoliquiritigenin targets GRP78 to chemosensitize breast cancer stem cells via \u03b2-catenin\/ABCG2 signaling","volume":"35","author":"Wang","year":"2014","journal-title":"Carcinogenesis"},{"issue":"2","key":"10.1016\/j.bcp.2026.118559_b0115","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1055\/s-2005-837779","article-title":"Isoliquiritigenin inhibits cell proliferation and induces apoptosis in human hepatoma cells","volume":"71","author":"Hsu","year":"2005","journal-title":"Planta Med."},{"issue":"45","key":"10.1016\/j.bcp.2026.118559_b0120","doi-asserted-by":"crossref","first-page":"73432","DOI":"10.18632\/oncotarget.12369","article-title":"Isoliquiritigenin induces apoptosis and autophagy and inhibits endometrial cancer growth in mice","volume":"7","author":"Wu","year":"2016","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.bcp.2026.118559_b0125","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1055\/s-0029-1240699","article-title":"The licorice flavonoid isoliquiritigenin suppresses phorbol ester-induced cyclooxygenase-2 expression in the non-tumorigenic MCF-10A breast cell line","volume":"76","author":"Lau","year":"2010","journal-title":"Planta Med."},{"issue":"5","key":"10.1016\/j.bcp.2026.118559_b0130","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/ijc.24046","article-title":"Dietary administration of the licorice flavonoid isoliquiritigenin deters the growth of MCF-7 cells overexpressing aromatase","volume":"124","author":"Ye","year":"2009","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2026.118559_b0135","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.taap.2013.05.031","article-title":"Isoliquiritigenin induces growth inhibition and apoptosis through downregulating arachidonic acid metabolic network and the deactivation of PI3K\/Akt in human breast cancer","volume":"272","author":"Li","year":"2013","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118559_b0140","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.taap.2014.07.018","article-title":"Downregulation of COX-2 and CYP 4A signaling by isoliquiritigenin inhibits human breast cancer metastasis through preventing anoikis resistance, migration and invasion","volume":"280","author":"Zheng","year":"2014","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118559_b0145","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1186\/s13046-019-1361-2","article-title":"Inhibition of COX-2, mPGES-1 and CYP4A by isoliquiritigenin blocks the angiogenic Akt signaling in glioma through ceRNA effect of miR-194-5p and lncRNA NEAT1","volume":"38","author":"Wang","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.bcp.2026.118559_b0150","doi-asserted-by":"crossref","first-page":"281","DOI":"10.15430\/JCP.2015.20.4.281","article-title":"Isoliquiritigenin inhibits metastatic breast cancer cell-induced receptor activator of nuclear factor kappa-B Ligand\/osteoprotegerin ratio in human osteoblastic cells","volume":"20","author":"Lee","year":"2015","journal-title":"J Cancer Prev"},{"issue":"3","key":"10.1016\/j.bcp.2026.118559_b0155","article-title":"Dietary compound isoliquiritigenin, an antioxidant from licorice, suppresses triple-negative breast tumor growth via apoptotic death program activation in cell and xenograft animal models","volume":"9","author":"Lin","year":"2020","journal-title":"Antioxidants (Basel)"},{"issue":"22","key":"10.1016\/j.bcp.2026.118559_b0160","first-page":"4475","article-title":"Total flavonoid from Glycyrrhizae Radix et Rhizoma and its ingredient isoliquiritigenin regulation M2 phenotype polarization of macrophages","volume":"40","author":"Wang","year":"2015","journal-title":"Zhongguo Zhong Yao Za Zhi"},{"issue":"8","key":"10.1016\/j.bcp.2026.118559_b0165","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1021\/acs.chemrestox.5b00157","article-title":"Differential effects of glycyrrhiza species on genotoxic estrogen metabolism: licochalcone a downregulates P450 1B1, whereas isoliquiritigenin stimulates it","volume":"28","author":"Dunlap","year":"2015","journal-title":"Chem. Res. Toxicol."},{"issue":"37","key":"10.1016\/j.bcp.2026.118559_b0170","doi-asserted-by":"crossref","first-page":"6786","DOI":"10.2174\/0929867325666181112091700","article-title":"Isoliquiritigenin (ISL) and its formulations: potential antitumor agents","volume":"26","author":"Zhao","year":"2019","journal-title":"Curr. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2026.118559_b0175","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1021\/acs.jnatprod.5b00774","article-title":"Cytotoxic evaluation against breast cancer cells of isoliquiritigenin analogues from Spatholobus suberectus and their synthetic derivatives","volume":"79","author":"Peng","year":"2016","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.bcp.2026.118559_b0180","doi-asserted-by":"crossref","first-page":"378","DOI":"10.3389\/fphar.2020.00378","article-title":"Isoliquiritigenin derivative regulates miR-374a\/BAX axis to suppress triple-negative breast cancer tumorigenesis and development","volume":"11","author":"Peng","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118559_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217734","article-title":"Isoliquiritigenin reduces brain metastasis by circNAV3-ST6GALNAC5-EGFR axis in triple-negative breast cancer","volume":"624","author":"Xie","year":"2025","journal-title":"Cancer Lett."},{"issue":"6","key":"10.1016\/j.bcp.2026.118559_b0190","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1142\/S0192415X2450071X","article-title":"Isoliquiritigenin suppresses breast tumor development by enhancing host antitumor immunity","volume":"52","author":"Yuan","year":"2024","journal-title":"Am. J. Chin. Med."},{"issue":"11","key":"10.1016\/j.bcp.2026.118559_b0195","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.32604\/or.2025.068292","article-title":"Isoliquiritigenin inhibits triple-negative breast cancer progression via targeting the IRF5\/SLC7A5\/IDO1-mediated tryptophan metabolism pathway","volume":"33","author":"Duan","year":"2025","journal-title":"Oncol. Res."},{"issue":"5","key":"10.1016\/j.bcp.2026.118559_b0200","doi-asserted-by":"crossref","first-page":"36","DOI":"10.32604\/or.2026.077059","article-title":"Isoliquiritigenin impedes breast cancer progression through PITX1-PFKP-mediated glycolysis reprogramming","volume":"34","author":"Liu","year":"2026","journal-title":"Oncol. Res."},{"issue":"12","key":"10.1016\/j.bcp.2026.118559_b0205","doi-asserted-by":"crossref","first-page":"9503","DOI":"10.1007\/s00210-024-03282-6","article-title":"An insight into the therapeutic effects of isoliquiritigenin in breast cancer","volume":"397","author":"Sharma","year":"2024","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118559_b0210","doi-asserted-by":"crossref","DOI":"10.5812\/ijpr-165301","article-title":"Isoliquiritigenin in breast cancer: a systematic review of its preventive and anti-metastatic mechanisms","volume":"24","author":"Xue","year":"2025","journal-title":"Iran J Pharm Res"},{"issue":"7","key":"10.1016\/j.bcp.2026.118559_b0215","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/bmc.3655","article-title":"The application of HPLC-MS\/MS to studies of pharmacokinetics and interconversion of isoliquiritigenin and neoisoliquiritigenin in rats","volume":"30","author":"Peng","year":"2016","journal-title":"Biomed. Chromatogr."},{"issue":"17","key":"10.1016\/j.bcp.2026.118559_b0220","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1055\/s-0033-1350924","article-title":"Pharmacokinetics of isoliquiritigenin and its metabolites in rats: low bioavailability is primarily due to the hepatic and intestinal metabolism","volume":"79","author":"Lee","year":"2013","journal-title":"Planta Med."},{"issue":"13","key":"10.1016\/j.bcp.2026.118559_b0225","doi-asserted-by":"crossref","first-page":"16329","DOI":"10.1021\/acsami.2c19029","article-title":"Tumor microenvironment-responsive nanoherb delivery system for synergistically inhibition of cancer stem cells","volume":"15","author":"Jia","year":"2023","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.bcp.2026.118559_b0230","doi-asserted-by":"crossref","DOI":"10.1186\/s12951-026-04671-0","article-title":"ISL@mTOMV nanoparticles: a promising approach for VM-targeted therapy in breast cancer","author":"Fu","year":"2026","journal-title":"J Nanobiotechnology"},{"key":"10.1016\/j.bcp.2026.118559_b0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.medidd.2025.100230","article-title":"A comprehensive review of structure activity relationships: exploration of chalcone derivatives as anticancer agents, target-based and cell line-specific insights","volume":"28","author":"Saifullah","year":"2025","journal-title":"Med. Drug Discovery"},{"issue":"1","key":"10.1016\/j.bcp.2026.118559_b0240","doi-asserted-by":"crossref","DOI":"10.3390\/ph17010043","article-title":"Isoliquiritigenin inhibits the growth of colorectal cancer cells through the ESR2\/PI3K\/AKT signalling pathway","volume":"17","author":"Luo","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"10.1016\/j.bcp.2026.118559_b0245","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20192727","article-title":"Isoliquiritigenin inhibits the proliferation, migration and metastasis of Hep3B cells via suppressing cyclin D1 and PI3K\/AKT pathway","volume":"40","author":"Huang","year":"2020","journal-title":"Biosci. Rep."},{"issue":"2","key":"10.1016\/j.bcp.2026.118559_b0250","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1142\/S0192415X21500233","article-title":"Isoliquiritigenin suppresses EMT-Induced metastasis in triple-negative breast cancer through miR-200c\/C-JUN\/\u03b2-catenin","volume":"49","author":"Peng","year":"2021","journal-title":"Am. J. Chin. Med."},{"issue":"18","key":"10.1016\/j.bcp.2026.118559_b0255","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2021108647","article-title":"Dynamic EMT: a multi-tool for tumor progression","volume":"40","author":"Brabletz","year":"2021","journal-title":"EMBO J."},{"issue":"5","key":"10.1016\/j.bcp.2026.118559_b0260","first-page":"6133","article-title":"Isoliquiritigenin inhibits cell proliferation and migration through the PI3K\/AKT signaling pathway in A549 lung cancer cells","volume":"16","author":"Tian","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.bcp.2026.118559_b0265","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-019-1351-4","article-title":"Cardamonin inhibits breast cancer growth by repressing HIF-1\u03b1-dependent metabolic reprogramming","volume":"38","author":"Jin","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.bcp.2026.118559_b0270","doi-asserted-by":"crossref","DOI":"10.1111\/cbdd.70145","article-title":"Exploring flavonoids as regulators of MMP-2 and MMP-9 in cancer pathogenesis","volume":"105","author":"Vo","year":"2025","journal-title":"Chem. Biol. Drug Des."},{"issue":"1","key":"10.1016\/j.bcp.2026.118559_b0275","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13578-024-01297-3","article-title":"Targeting stress induction of GRP78 by cardiac glycoside oleandrin dually suppresses cancer and COVID-19","volume":"14","author":"Ha","year":"2024","journal-title":"Cell Biosci."},{"issue":"1","key":"10.1016\/j.bcp.2026.118559_b0280","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13045-020-00901-6","article-title":"Emerging agents that target signaling pathways in cancer stem cells","volume":"13","author":"Yang","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118559_b0285","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines14010215","article-title":"Targeting cancer stem cells with phytochemicals: molecular mechanisms and therapeutic potential","volume":"14","author":"Sah","year":"2026","journal-title":"Biomedicines"},{"key":"10.1016\/j.bcp.2026.118559_b0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2022.154524","article-title":"Targeting cancer stem cells and signalling pathways through phytochemicals: a promising approach against colorectal cancer","volume":"108","author":"Liao","year":"2023","journal-title":"Phytomedicine"},{"key":"10.1016\/j.bcp.2026.118559_b0295","article-title":"Targeting digestive system cancers with isoliquiritigenin: a comprehensive review of antitumor mechanisms","volume":"16","author":"Li","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118559_b0300","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.3390\/ijms18102025","article-title":"Isoliquiritigenin induces autophagy and inhibits ovarian cancer cell growth","volume":"18","author":"Chen","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"16","key":"10.1016\/j.bcp.2026.118559_b0305","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.18632\/oncotarget.2192","article-title":"MicroRNA-25 regulates chemoresistance-associated autophagy in breast cancer cells, a process modulated by the natural autophagy inducer isoliquiritigenin","volume":"5","author":"Wang","year":"2014","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.bcp.2026.118559_b0310","doi-asserted-by":"crossref","DOI":"10.3390\/ph14111068","article-title":"New insights into curcumin- and resveratrol-mediated anti-cancer effects","volume":"14","author":"Arena","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.bcp.2026.118559_b0315","article-title":"Resveratrol, piceatannol, curcumin, and quercetin as therapeutic targets in gastric cancer\u2014mechanisms and clinical implications for natural products","volume":"3","author":"Warias","year":"2025","journal-title":"Molecules"},{"key":"10.1016\/j.bcp.2026.118559_b0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2022.154117","article-title":"Isoliquiritigenin alleviates liver fibrosis through caveolin-1-mediated hepatic stellate cells ferroptosis in zebrafish and mice","volume":"101","author":"Huang","year":"2022","journal-title":"Phytomedicine"},{"key":"10.1016\/j.bcp.2026.118559_b0325","article-title":"The role of natural product chemistry in drug discovery: two decades of progress and perspectives","volume":"89","author":"Butler","year":"2025","journal-title":"J. Nat. Prod."},{"issue":"1","key":"10.1016\/j.bcp.2026.118559_b0330","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1208\/s12248-012-9432-8","article-title":"Therapeutic roles of curcumin: lessons learned from clinical trials","volume":"15","author":"Gupta","year":"2013","journal-title":"AAPS J."},{"key":"10.1016\/j.bcp.2026.118559_b0335","article-title":"In vivo gastroprotective effect along with pharmacokinetics, tissue distribution and metabolism of isoliquiritigenin in mice","volume":"81","author":"Choi","year":"2015","journal-title":"Planta Med."},{"issue":"2","key":"10.1016\/j.bcp.2026.118559_b0340","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1124\/dmd.107.018721","article-title":"In vitro metabolism of isoliquiritigenin by human liver microsomes","volume":"36","author":"Guo","year":"2008","journal-title":"Drug Metab. Dispos."},{"issue":"2","key":"10.1016\/j.bcp.2026.118559_b0345","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1158\/1940-6207.CAPR-09-0049","article-title":"Cancer chemopreventive activity and metabolism of isoliquiritigenin, a compound found in licorice","volume":"3","author":"Cuendet","year":"2010","journal-title":"Cancer Prev. Res. (Phila.)"},{"key":"10.1016\/j.bcp.2026.118559_b0350","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3390\/cancers13010115","article-title":"Perspectives on the role of isoliquiritigenin in cancer","author":"Wang","year":"2021","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.bcp.2026.118559_b0355","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1124\/dmd.108.021857","article-title":"Biotransformation of the chemopreventive agent 2\u2032,4\u2032,4-trihydroxychalcone (isoliquiritigenin) by UDP-glucuronosyltransferases","volume":"36","author":"Guo","year":"2008","journal-title":"Drug Metab. Dispos."},{"issue":"10","key":"10.1016\/j.bcp.2026.118559_b0360","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13101715","article-title":"Improving curcumin bioavailability: current strategies and future perspectives","volume":"13","author":"Tabanelli","year":"2021","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.bcp.2026.118559_b0365","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00280-010-1525-4","article-title":"Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats","volume":"68","author":"Kapetanovic","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118559_b0370","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.phymed.2018.07.004","article-title":"Isoliquiritigenin exerts antioxidant activity in Caenorhabditis elegans via insulin-like signaling pathway and SKN-1","volume":"55","author":"Link","year":"2019","journal-title":"Phytomedicine"},{"issue":"10","key":"10.1016\/j.bcp.2026.118559_b0375","doi-asserted-by":"crossref","DOI":"10.3390\/ph15101250","article-title":"Chalcone: a promising bioactive scaffold in medicinal chemistry","volume":"15","author":"Rajendran","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.bcp.2026.118559_b0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2025.157652","article-title":"Natural compound-nanoparticle therapies for breast cancer: a review from 2018-2025","volume":"150","author":"Zhang","year":"2026","journal-title":"Phytomedicine"},{"key":"10.1016\/j.bcp.2026.118559_b0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105974","article-title":"Effects and mechanisms of dietary bioactive compounds on breast cancer prevention","volume":"178","author":"Ganesan","year":"2022","journal-title":"Pharmacol. Res."},{"issue":"11","key":"10.1016\/j.bcp.2026.118559_b0390","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13111829","article-title":"Targeting engineered nanoparticles for breast cancer therapy","volume":"13","author":"Ganesan","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bcp.2026.118559_b0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.eurpolymj.2022.111723","article-title":"Insights into PLGA-encapsulated epigallocatechin 3-gallate nanoparticles as a new potential biomedical system: a computational and experimental approach","volume":"182","author":"Minnelli","year":"2023","journal-title":"Eur. Polym. J."},{"issue":"5","key":"10.1016\/j.bcp.2026.118559_b0400","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1208\/s12249-020-01710-3","article-title":"A combinational approach towards treatment of breast cancer: an analysis of noscapine-loaded polymeric nanoparticles and doxorubicin","volume":"21","author":"Esnaashari","year":"2020","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.bcp.2026.118559_b0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2025.123568","article-title":"Chrono-controlled hydrogel platform orchestrates metabolic reprogramming and cuproptosis-driven immune activation against triple-negative breast cancer","volume":"325","author":"Lu","year":"2026","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.bcp.2026.118559_b0410","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ncrna.2016.07.001","article-title":"Current state of phenolic and terpenoidal dietary factors and natural products as non-coding RNA\/microRNA modulators for improved cancer therapy and prevention","volume":"1","author":"Biersack","year":"2016","journal-title":"Noncoding RNA Res"},{"issue":"6","key":"10.1016\/j.bcp.2026.118559_b0415","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1021\/mp700113r","article-title":"Bioavailability of curcumin: problems and promises","volume":"4","author":"Anand","year":"2007","journal-title":"Mol. Pharm."},{"issue":"1\u20132","key":"10.1016\/j.bcp.2026.118559_b0420","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.drudis.2011.09.009","article-title":"Curcumin nanoformulations: a future nanomedicine for cancer","volume":"17","author":"Yallapu","year":"2012","journal-title":"Drug Discov. Today"},{"issue":"2","key":"10.1016\/j.bcp.2026.118559_b0425","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ijpharm.2015.01.003","article-title":"Resveratrol nanoformulations: challenges and opportunities","volume":"479","author":"Summerlin","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.bcp.2026.118559_b0430","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.649395","article-title":"Resveratrol-based nanoformulations as an emerging therapeutic strategy for cancer","volume":"8","author":"Sharifi-Rad","year":"2021","journal-title":"Front. Mol. Biosci."},{"issue":"31","key":"10.1016\/j.bcp.2026.118559_b0435","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","article-title":"Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer","volume":"23","author":"Gradishar","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.118559_b0440","article-title":"Flavonoids loaded in nanocarriers: an opportunity to increase oral bioavailability and bioefficacy","volume":"05","author":"Bilia","year":"2014","journal-title":"Food Nutr. Sci."},{"key":"10.1016\/j.bcp.2026.118559_b0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.nanoso.2019.100397","article-title":"Recent developments in functionalized polymer nanoparticles for efficient drug delivery system","volume":"20","author":"Sur","year":"2019","journal-title":"Nano-Struct. Nano-Objects"},{"key":"10.1016\/j.bcp.2026.118559_b0450","doi-asserted-by":"crossref","first-page":"4147","DOI":"10.2147\/IJN.S134148","article-title":"iRGD-modified lipid-polymer hybrid nanoparticles loaded with isoliquiritigenin to enhance anti-breast cancer effect and tumor-targeting ability","volume":"12","author":"Gao","year":"2017","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.bcp.2026.118559_b0455","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jconrel.2019.05.044","article-title":"The beginning of the end of the nanomedicine hype","volume":"305","author":"Park","year":"2019","journal-title":"J. Control. Release"},{"issue":"6","key":"10.1016\/j.bcp.2026.118559_b0460","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2217\/nnm.16.17","article-title":"Emerging nanomedicine applications and manufacturing: progress and challenges","volume":"11","author":"Sartain","year":"2016","journal-title":"Nanomedicine (Lond.)"},{"key":"10.1016\/j.bcp.2026.118559_b0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2022.103922","article-title":"A tumor-targeted delivery of oral isoliquiritigenin through encapsulated zein phosphatidylcholine hybrid nanoparticles prevents triple-negative breast cancer","volume":"79","author":"Wang","year":"2023","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.bcp.2026.118559_b0470","doi-asserted-by":"crossref","unstructured":"L. Andr\u00e9 de Almeida Campos, A. Francisco Silva Neto, M. Cec\u00edlia Souza Noronha, M. Ferreira de Lima, I. Mac\u00e1rio Ferro Cavalcanti, N. Stela Santos-Magalh\u00e3es, Zein nanoparticles for drug delivery: Preparation methods and biological applications, International Journal of Pharmaceutics 635 (2023) 122754.","DOI":"10.1016\/j.ijpharm.2023.122754"},{"issue":"6","key":"10.1016\/j.bcp.2026.118559_b0475","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.addr.2011.12.009","article-title":"Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers","volume":"64","author":"Ensign","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"22","key":"10.1016\/j.bcp.2026.118559_b0480","doi-asserted-by":"crossref","DOI":"10.3390\/polym13224036","article-title":"Recent advancement in chitosan-based nanoparticles for improved oral bioavailability and bioactivity of phytochemicals, challenges and perspectives","volume":"13","author":"Imam","year":"2021","journal-title":"Polymers (Basel)"},{"key":"10.1016\/j.bcp.2026.118559_b0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2024.111037","article-title":"Cryoprotective isoliquiritigenin-zein phosphatidylcholine nanoparticles inhibits breast cancer-bone metastasis by targeting JAK-STAT signaling pathways","volume":"396","author":"Ganesan","year":"2024","journal-title":"Chem. Biol. Interact."},{"issue":"7","key":"10.1016\/j.bcp.2026.118559_b0490","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1248\/cpb.c20-00017","article-title":"Bone-targeted drug delivery systems and strategies for treatment of bone metastasis","volume":"68","author":"Katsumi","year":"2020","journal-title":"Chem. Pharm Bull. (Tokyo)"},{"issue":"17","key":"10.1016\/j.bcp.2026.118559_b0495","doi-asserted-by":"crossref","first-page":"17014","DOI":"10.1021\/acsnano.5c04743","article-title":"Bone-targeting nucleic acid delivery polymer vector for effective therapy of bone metastasis","volume":"19","author":"Li","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.bcp.2026.118559_b0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2024.105609","article-title":"Isoliquiritigenin-infused electrospun nanofiber inhibits breast cancer proliferation and invasion through downregulation of PI3K\/Akt\/mTOR and MMP2\/9 pathways","volume":"96","author":"Ganesan","year":"2024","journal-title":"J. Drug Delivery Sci. Technol."},{"issue":"12","key":"10.1016\/j.bcp.2026.118559_b0505","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1586\/14737140.2013.840090","article-title":"The role of Gliadel wafers in the treatment of high-grade gliomas","volume":"13","author":"Bregy","year":"2013","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"2","key":"10.1016\/j.bcp.2026.118559_b0510","doi-asserted-by":"crossref","first-page":"234","DOI":"10.37349\/eds.2024.00044","article-title":"Subacute toxicity of isoliquiritigenin-zein phosphatidylcholine nanoparticles on biochemical, hematological, and histopathological parameters in Sprague-Dawley rats","volume":"2","author":"Yang","year":"2024","journal-title":"Explor. Drug Sci."},{"issue":"2","key":"10.1016\/j.bcp.2026.118559_b0515","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jconrel.2013.05.025","article-title":"Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines","volume":"172","author":"Dobrovolskaia","year":"2013","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.bcp.2026.118559_b0520","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cell.2015.08.068","article-title":"Preclinical mouse cancer models: a maze of opportunities and challenges","volume":"163","author":"Day","year":"2015","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.bcp.2026.118559_b0525","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/wnan.1338","article-title":"Product quality for nanomaterials: current U.S. experience and perspective","volume":"7","author":"Tyner","year":"2015","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"issue":"7391","key":"10.1016\/j.bcp.2026.118559_b0530","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/483531a","article-title":"Drug development: raise standards for preclinical cancer research","volume":"483","author":"Begley","year":"2012","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.bcp.2026.118559_b0535","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1002165","article-title":"The economics of reproducibility in preclinical research","volume":"13","author":"Freedman","year":"2015","journal-title":"PLoS Biol."},{"issue":"7419","key":"10.1016\/j.bcp.2026.118559_b0540","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nature11556","article-title":"A call for transparent reporting to optimize the predictive value of preclinical research","volume":"490","author":"Landis","year":"2012","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.bcp.2026.118559_b0545","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1038\/psp.2013.41","article-title":"Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development","volume":"2","author":"Jones","year":"2013","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"issue":"11","key":"10.1016\/j.bcp.2026.118559_b0550","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1124\/dmd.115.065920","article-title":"Physiologically based pharmacokinetic (PBPK) modeling and simulation approaches: a systematic review of published models, applications, and model verification","volume":"43","author":"Sager","year":"2015","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.bcp.2026.118559_b0555","doi-asserted-by":"crossref","first-page":"103","DOI":"10.5507\/bp.2010.017","article-title":"Phase II drug metabolizing enzymes","volume":"154","author":"Jancova","year":"2010","journal-title":"Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub."},{"key":"10.1016\/j.bcp.2026.118559_b0560","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/nyas.12403","article-title":"Nanomedicines: addressing the scientific and regulatory gap","volume":"1313","author":"Tinkle","year":"2014","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.bcp.2026.118559_b0565","series-title":"Cancer Imaging","first-page":"139","article-title":"A. Gregory Sorensen, H.H. Pien, 11 - Role of Imaging Biomarkers in Drug Development","author":"Miller","year":"2008"},{"key":"10.1016\/j.bcp.2026.118559_b0570","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/clpt.2010.273","article-title":"Changes to ICH guideline M3: new and revised guidance on nonclinical safety studies to support human clinical trials and marketing authorization","volume":"89","author":"Ledwith","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.bcp.2026.118559_b0575","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nm.3853","article-title":"Translational value of mouse models in oncology drug development","volume":"21","author":"Gould","year":"2015","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.bcp.2026.118559_b0580","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1158\/2159-8290.CD-14-0001","article-title":"Patient-derived xenograft models: an emerging platform for translational cancer research","volume":"4","author":"Hidalgo","year":"2014","journal-title":"Cancer Discov."},{"issue":"1\u20132","key":"10.1016\/j.bcp.2026.118559_b0585","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.cell.2014.12.021","article-title":"Organoid models of human and mouse ductal pancreatic cancer","volume":"160","author":"Boj","year":"2015","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.bcp.2026.118559_b0590","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/carcin\/bgh261","article-title":"Modeling metastasis in vivo","volume":"26","author":"Khanna","year":"2005","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bcp.2026.118559_b0595","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s12935-020-01418-1","article-title":"EO771, the first luminal B mammary cancer cell line from C57BL\/6 mice","volume":"20","author":"Le Naour","year":"2020","journal-title":"Cancer Cell Int."},{"issue":"5981","key":"10.1016\/j.bcp.2026.118559_b0600","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1126\/science.1183057","article-title":"Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs","volume":"328","author":"Sugahara","year":"2010","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.bcp.2026.118559_b0605","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1158\/2159-8290.CD-20-1311","article-title":"Liquid biopsy: from discovery to clinical application","volume":"11","author":"Alix-Panabi\u00e8res","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bcp.2026.118559_b0610","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/bs.acc.2019.01.006","article-title":"A practical guide to validation and verification of analytical methods in the clinical laboratory","volume":"90","author":"Pum","year":"2019","journal-title":"Adv. Clin. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2026.118559_b0615","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/cts.12635","article-title":"Regulatory affairs 101: introduction to investigational new drug applications and clinical trial applications","volume":"12","author":"Chiodin","year":"2019","journal-title":"Clin. Transl. Sci."},{"issue":"7","key":"10.1016\/j.bcp.2026.118559_b0620","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.addr.2011.02.004","article-title":"Novel strategies for microdose studies using non-radiolabeled compounds","volume":"63","author":"Maeda","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.bcp.2026.118559_b0625","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrc2066","article-title":"Compressing drug development timelines in oncology using phase '0' trials","volume":"7","author":"Kummar","year":"2007","journal-title":"Nat. Rev. Cancer"},{"issue":"3\u20134","key":"10.1016\/j.bcp.2026.118559_b0630","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.drudis.2009.11.006","article-title":"Can molecular biomarker-based patient selection in phase I trials accelerate anticancer drug development?","volume":"15","author":"Carden","year":"2010","journal-title":"Drug Discov. Today"},{"issue":"1","key":"10.1016\/j.bcp.2026.118559_b0635","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s41231-019-0050-7","article-title":"Lost in translation: the valley of death across preclinical and clinical divide \u2013 identification of problems and overcoming obstacles","volume":"4","author":"Seyhan","year":"2019","journal-title":"Transl. Med. Commun."},{"key":"10.1016\/j.bcp.2026.118559_b0640","article-title":"Isoliquiritigenin: a natural compound with a promising role in inhibiting breast cancer lung metastasis","author":"Ganesan","year":"2024","journal-title":"J. Tradit. Complement. Med."},{"issue":"6","key":"10.1016\/j.bcp.2026.118559_b0645","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1208\/s12248-015-9811-z","article-title":"Therapeutic applications of curcumin nanoformulations","volume":"17","author":"Yallapu","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.bcp.2026.118559_b0650","doi-asserted-by":"crossref","first-page":"6027","DOI":"10.2147\/IJN.S132434","article-title":"Liposomal curcumin and its application in cancer","volume":"12","author":"Feng","year":"2017","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.bcp.2026.118559_b0655","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2147\/JEP.S70568","article-title":"New insights into therapeutic activity and anticancer properties of curcumin","volume":"9","author":"Panda","year":"2017","journal-title":"J. Exp. Pharmacol."},{"issue":"16","key":"10.1016\/j.bcp.2026.118559_b0660","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2217\/nnm-2022-0064","article-title":"Synergistic chemo-photothermal and ferroptosis therapy of polydopamine nanoparticles for esophageal cancer","volume":"17","author":"Chen","year":"2022","journal-title":"Nanomedicine (Lond.)"},{"key":"10.1016\/j.bcp.2026.118559_b0665","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1749-6632.2010.05842.x","article-title":"Bioavailability of resveratrol","volume":"1215","author":"Walle","year":"2011","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"2","key":"10.1016\/j.bcp.2026.118559_b0670","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/17425247.2024.2317194","article-title":"Nanotechnology-mediated delivery of resveratrol as promising strategy to improve therapeutic efficacy in triple negative breast cancer (TNBC): progress and promises","volume":"21","author":"Ahmad","year":"2024","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.bcp.2026.118559_b0675","first-page":"177","article-title":"Novel resveratrol nanodelivery systems based on lipid nanoparticles to enhance its oral bioavailability","volume":"8","author":"Neves","year":"2013","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.bcp.2026.118559_b0680","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.colsurfb.2019.04.030","article-title":"Nanotechnology-based formulations for resveratrol delivery: Effects on resveratrol in vivo bioavailability and bioactivity","volume":"180","author":"Santos","year":"2019","journal-title":"Colloids Surf. B Biointerfaces"},{"issue":"9","key":"10.1016\/j.bcp.2026.118559_b0685","doi-asserted-by":"crossref","first-page":"5592","DOI":"10.3390\/ijms12095592","article-title":"Epigallocatechin-3-gallate (EGCG) for clinical trials: more pitfalls than promises?","volume":"12","author":"Mereles","year":"2011","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.bcp.2026.118559_b0690","doi-asserted-by":"crossref","DOI":"10.3390\/nu8050307","article-title":"Epigallocatechin gallate nanodelivery systems for cancer therapy","volume":"8","author":"Granja","year":"2016","journal-title":"Nutrients"},{"key":"10.1016\/j.bcp.2026.118559_b0695","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.809706","article-title":"Epigallocatechin-3-gallate delivery in lipid-based nanoparticles: potentiality and perspectives for future applications in cancer chemoprevention and therapy","volume":"13","author":"Farabegoli","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"9","key":"10.1016\/j.bcp.2026.118559_b0700","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23092346","article-title":"Bioavailability of tea catechins and its improvement","volume":"23","author":"Cai","year":"2018","journal-title":"Molecules"},{"issue":"13","key":"10.1016\/j.bcp.2026.118559_b0705","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28135246","article-title":"Epigallocatechin-3-gallate therapeutic potential in cancer: mechanism of action and clinical implications","volume":"28","author":"Kciuk","year":"2023","journal-title":"Molecules"},{"issue":"20","key":"10.1016\/j.bcp.2026.118559_b0710","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.2174\/09298673113209990120","article-title":"Bioavailability of quercetin: problems and promises","volume":"20","author":"Cai","year":"2013","journal-title":"Curr. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2026.118559_b0715","doi-asserted-by":"crossref","first-page":"E108","DOI":"10.3390\/molecules21010108","article-title":"Application of bioactive quercetin in oncotherapy: from nutrition to nanomedicine","volume":"21","author":"Nam","year":"2016","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.bcp.2026.118559_b0720","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s13318-018-0517-3","article-title":"Improved oral absorption of quercetin from quercetin Phytosome\u00ae, a new delivery system based on food grade lecithin","volume":"44","author":"Riva","year":"2019","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"issue":"7","key":"10.1016\/j.bcp.2026.118559_b0725","doi-asserted-by":"crossref","DOI":"10.3390\/ph16071020","article-title":"Recent advances in potential health benefits of quercetin","volume":"16","author":"Aghababaei","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.bcp.2026.118559_b0730","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114068","article-title":"Quercetin derivatives: Drug design, development, and biological activities, a review","volume":"229","author":"Alizadeh","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"11","key":"10.1016\/j.bcp.2026.118559_b0735","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1158\/1078-0432.CCR-04-2291","article-title":"Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol)","volume":"11","author":"Sparreboom","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.bcp.2026.118559_b0740","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/annonc\/mdl104","article-title":"Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer","volume":"17","author":"Green","year":"2006","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118559_b0745","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jconrel.2013.05.041","article-title":"nab-Paclitaxel mechanisms of action and delivery","volume":"170","author":"Yardley","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bcp.2026.118559_b0750","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.2147\/DDDT.S88023","article-title":"Albumin-bound paclitaxel in solid tumors: clinical development and future directions","volume":"9","author":"Kundranda","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.bcp.2026.118559_b0755","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115171","article-title":"Design, synthesis and evaluation of the novel chalcone derivatives with 2,2-dimethylbenzopyran as HIF-1 inhibitors that possess anti-angiogenic potential","volume":"250","author":"Xu","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2026.118559_b0760","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s12672-025-03465-4","article-title":"PTEN defects in cancer, from gene to protein molecular causes and therapeutic targets","volume":"16","author":"Khasarah","year":"2025","journal-title":"Discov. Oncol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118559_b0765","first-page":"3429","article-title":"Isoliquiritigenin inhibits proliferation and metastasis of MKN28 gastric cancer cells by suppressing the PI3K\/AKT\/mTOR signaling pathway","volume":"18","author":"Zhang","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.bcp.2026.118559_b0770","article-title":"Cardamonin induces apoptosis of colorectal cancer cells via targeted inhibition of the JAK\/STAT3\/epithelial-mesenchymal transition (EMT) signaling axis","volume":"16","author":"Wu","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.bcp.2026.118559_b0775","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1158\/0008-5472.CAN-07-0325","article-title":"GRP78 induction in cancer: therapeutic and prognostic implications","volume":"67","author":"Lee","year":"2007","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.bcp.2026.118559_b0780","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/carcin\/bgi379","article-title":"Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer","volume":"27","author":"Ai","year":"2006","journal-title":"Carcinogenesis"},{"issue":"5930","key":"10.1016\/j.bcp.2026.118559_b0785","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: the metabolic requirements of cell proliferation","volume":"324","author":"Vander Heiden","year":"2009","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.bcp.2026.118559_b0790","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/s41418-019-0474-7","article-title":"Autophagy in cancer: moving from understanding mechanism to improving therapy responses in patients","volume":"27","author":"Mulcahy Levy","year":"2020","journal-title":"Cell Death Differ."},{"issue":"4","key":"10.1016\/j.bcp.2026.118559_b0795","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.3892\/ijo.2012.1325","article-title":"Resveratrol induces apoptosis via ROS-triggered autophagy in human colon cancer cells","volume":"40","author":"Miki","year":"2012","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bcp.2026.118559_b0800","article-title":"Anti-migratory properties of cryoprotective isoliquiritigenin-zein phosphatidylcholine nanoparticles prevent triple-negative breast cancer through PI3K-mTOR and MMP2\/9 pathways","author":"Xu","year":"2023","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118559_b0805","article-title":"Chemotherapy and dietary phytochemical agents","volume":"2012","author":"Sak","year":"2012","journal-title":"Chemother Res Pract"},{"issue":"6","key":"10.1016\/j.bcp.2026.118559_b0810","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1158\/0008-5472.CAN-09-2840","article-title":"Constitutively active Stat3 enhances neu-mediated migration and metastasis in mammary tumors via upregulation of Cten","volume":"70","author":"Barbieri","year":"2010","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.bcp.2026.118559_b0815","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jconrel.2010.08.027","article-title":"To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery","volume":"148","author":"Danhier","year":"2010","journal-title":"J. Control. Release"},{"issue":"12","key":"10.1016\/j.bcp.2026.118559_b0820","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nnano.2007.387","article-title":"Nanocarriers as an emerging platform for cancer therapy","volume":"2","author":"Peer","year":"2007","journal-title":"Nat. Nanotechnol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118559_b0825","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijpharm.2005.10.010","article-title":"Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles","volume":"307","author":"Owens","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.bcp.2026.118559_b0830","doi-asserted-by":"crossref","DOI":"10.1016\/j.nwnano.2026.100182","article-title":"Targeted nanotechnology in bone cancer: Integrating stimuli responsive drug delivery and artificial intelligence for personalized therapy","volume":"13","author":"Dave","year":"2026","journal-title":"Nano Trends"},{"issue":"1","key":"10.1016\/j.bcp.2026.118559_b0835","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41413-024-00356-2","article-title":"Bone targeted nano-drug and nano-delivery","volume":"12","author":"Wu","year":"2024","journal-title":"Bone Res."},{"key":"10.1016\/j.bcp.2026.118559_b0840","doi-asserted-by":"crossref","DOI":"10.1007\/s12668-012-0060-7","article-title":"Nanotechnology as emerging tool for enhancing solubility of poorly water-soluble drugs","volume":"2","author":"Kumar","year":"2012","journal-title":"BioNanoScience"},{"issue":"1","key":"10.1016\/j.bcp.2026.118559_b0845","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0939-6411(00)00087-4","article-title":"Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art","volume":"50","author":"M\u00fcller","year":"2000","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"5","key":"10.1016\/j.bcp.2026.118559_b0850","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1124\/mol.119.116129","article-title":"Isoliquiritigenin, an orally available natural FLT3 inhibitor from licorice, exhibits selective anti-acute myeloid leukemia efficacy in vitro and in vivo","volume":"96","author":"Cao","year":"2019","journal-title":"Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118559_b0855","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s13046-018-0844-x","article-title":"Isoliquiritigenin suppresses human melanoma growth by targeting miR-301b\/LRIG1 signaling","volume":"37","author":"Xiang","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.bcp.2026.118559_b0860","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd2115","article-title":"Angiogenesis: an organizing principle for drug discovery?","volume":"6","author":"Folkman","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7347","key":"10.1016\/j.bcp.2026.118559_b0865","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10144","article-title":"Molecular mechanisms and clinical applications of angiogenesis","volume":"473","author":"Carmeliet","year":"2011","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bcp.2026.118559_b0870","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1186\/s12917-022-03414-1","article-title":"Anti-inflammation of isoliquiritigenin via the inhibition of NF-\u03baB and MAPK in LPS-stimulated MAC-T cells","volume":"18","author":"Li","year":"2022","journal-title":"BMC Vet. Res."},{"issue":"2","key":"10.1016\/j.bcp.2026.118559_b0875","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s12263-011-0210-5","article-title":"Dietary chalcones with chemopreventive and chemotherapeutic potential","volume":"6","author":"Orlikova","year":"2011","journal-title":"Genes Nutr."},{"issue":"12","key":"10.1016\/j.bcp.2026.118559_b0880","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/j.bcp.2010.06.036","article-title":"Cancer chemoprevention by dietary polyphenols: promising role for epigenetics","volume":"80","author":"Link","year":"2010","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118559_b0885","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.immuni.2013.06.014","article-title":"Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance","volume":"39","author":"Zitvogel","year":"2013","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.bcp.2026.118559_b0890","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrclinonc.2015.209","article-title":"Combination cancer immunotherapies tailored to the tumour microenvironment","volume":"13","author":"Smyth","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226009020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226009020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:20:35Z","timestamp":1792682435000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226009020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":178,"alternative-id":["S0006295226009020"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118559","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Isoliquiritigenin in breast cancer therapy: from mechanistic insights to advanced nano-enabled delivery strategies","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118559","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"118559"}}